ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study

BACKGROUND: The ExtaviJect® 30G autoinjector was developed to facilitate parenteral self-administration of interferon beta-1b (Extavia®), a first-line disease-modifying therapy in patients with multiple sclerosis. Our aim was to assess patient compliance with treatment when using the autoinjector, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Boeru, Gabriel, Milanov, Ivan, De Robertis, Francesca, Kozubski, Wojciech, Lang, Michael, Rojas-Farreras, Sònia, Tomlinson, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832381/
https://www.ncbi.nlm.nih.gov/pubmed/24255602
http://dx.doi.org/10.2147/MDER.S52590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832381/
https://www.ncbi.nlm.nih.gov/pubmed/24255602
http://dx.doi.org/10.2147/MDER.S52590

Ejemplares similares